Arthritis drugs roundups to be shared

 

Pfizer Inc. said 20 abstracts for XELJANZ® (tofacitinib citrate) will be presented at the upcoming ACR/ARHP Annual Meeting next week in Washington, D.C.

XELJANZ®/XELJANZ XR® (tofacitinib citrate) is a prescription medicine called a Janus kinase (JAK) inhibitor. The presentations held next week include results from two Oral Psoriatic Arthritis Trial called Phase 3 OPAL, as well as updated research for XELJANZ for rheumatoid arthritis patients.

“As part of our commitment to inflammation and immunology, we continue to advance our leading science in the research of Janus kinase inhibition,” said Michael Corbo, chief development officer, Inflammation & Immunology, Pfizer Global Product Development. “The extensive data being presented at this year's ACR/AHRP annual meeting expands upon our knowledge about the role of XELJANZ for the treatment of moderate to severe rheumatoid arthritis and also highlights its potential, if approved, for the treatment of psoriatic arthritis.”